The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Merck opens first climate-neutral manufacturing facility in Ireland
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Cagrilintide represents a novel approach to obesity management
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The company is bringing precision therapies for gynaecological cancers
Subscribe To Our Newsletter & Stay Updated
